US Patent

US7214695 — Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding

Composition of Matter · Assigned to Scripps Research Institute · Expires 2026-12-19 · 1y remaining

Vulnerability score 22/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compositions and methods for stabilizing the protein transthyretin and preventing its misfolding.

USPTO Abstract

Kinetic stabilization of the native state of transthyretin is an effective mechanism for preventing protein misfolding. Because transthyretin misfolding plays an important role in transthyretin amyloid diseases, inhibiting such misfolding can be used as an effective treatment or prophylaxis for such diseases. Treatment methods, screening methods, as well as specific transthyretin stabilizing compounds are disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
US7214695
Jurisdiction
US
Classification
Composition of Matter
Expires
2026-12-19
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Scripps Research Institute
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.